Filing Analysis
Black Diamond Therapeutics, Inc. announced its financial results for the six months ended June 30, 2026. The filing serves as a formal announcement of periodic financial performance via an attached press release.
📋 Key Facts
- Reporting period: Six months ended June 30, 2026.
- Announcement date: August 5, 2026.
- The report includes results of operations and financial condition under Item 2.02.
Black Diamond Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. The meeting resulted in the election of two new directors and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held via virtual-only format on June 26, 2026.
- Quorum was established with 44,690,495 shares present/represented out of 57,301,774 outstanding.
- Shannon Campbell and Kapil Dhingra were elected to the Board as Class III directors.
- PricewaterhouseCoopers LLP was ratified as independent registered public accounting firm for FY2026.
- Stockholders approved non-binding advisory votes on executive compensation (Say-on-Pay) and determined future Say-on-Pay votes will occur annually.
Black Diamond Therapeutics announced positive Phase 2 clinical trial results for its drug candidate, silevertinib, in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations. The trial demonstrated a preliminary median progression-free survival of 15.2 months and a 60% objective response rate, supporting advancement to pivotal development.
📋 Key Facts
- Enrolled 43 frontline NSCLC patients with EGFR non-classical mutations, including 19 with brain metastases.
- Preliminary median progression-free survival (PFS) is 15.2 months, and median duration of response (DOR) has not yet been reached.
- The overall Objective Response Rate (ORR) was 60%, and the Disease Control Rate (DCR) was 91%.
- CNS Objective Response Rate (ORR) was 86% among patients with measurable central nervous system lesions.
- Safety and efficacy data support a 150 mg QD dose for pivotal development, with Grade 3 or higher treatment-related adverse events reduced to 28% following dose reduction.
Black Diamond Therapeutics, Inc. (BDTX) reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The report was filed on May 7, 2026, which is also the date of the earliest event reported.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full press release with the financial announcement.
Black Diamond Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the fiscal year ended December 31, 2025.
- Financial results reported for the three months ended December 31, 2025.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Brent Hatzis-Schoch, COO and General Counsel.
Black Diamond Therapeutics announced positive preliminary Phase 2 data for silevertinib in NSCLC patients, including a 60% objective response rate and high CNS activity. The company also updated its cash runway guidance, stating current funds should last into the second half of 2028, contingent on trial funding and potential partnerships.
🚩 Red Flags
- Cash runway projections are contingent on external factors: specifically, funding for the GBM trial and a potential partnership for NSCLC.
📋 Key Facts
- Silevertinib Phase 2 NSCLC data (43 patients): 60% Objective Response Rate (ORR) and 86% CNS ORR.
- Cash runway: ~$135.5M as of Sept 30, 2025, expected to fund operations into H2 2028.
- Planned Phase 2 trial for newly diagnosed GBM to initiate in H1 2026 with ~150 patients.
- Company is actively seeking a partner for pivotal development of silevertinib in NSCLC.
Black Diamond Therapeutics, Inc. announced its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2025.
- Filing date: November 6, 2025.
- The report includes results of operations and financial condition under Item 2.02.
Black Diamond Therapeutics, Inc. announced its financial results for the three and six months ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2025.
- Announcement date: August 7, 2025.
- The filing includes Exhibit 99.1 containing the full text of the press release.
Black Diamond Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. The meeting resulted in the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held via virtual-only webcast on June 12, 2025.
- Quorum established with 42,988,581 shares present/represented out of 56,676,716 outstanding.
- Ali Behbahani, Garry E. Menzel, and Samarth Kulkarni were elected to the Board as Class II directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Black Diamond Therapeutics, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and includes the associated press release as an exhibit.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025
- Filing date: May 12, 2025
- The filing contains results of operations and financial condition under Item 2.02.
- Press release issued as Exhibit 99.1.
Black Diamond Therapeutics has entered into a significant global licensing agreement with Servier Pharmaceuticals for the development and commercialization of BDTX-4933, targeting RAF/RAS-mutant solid tumors. The deal provides substantial upfront cash and potential milestone payments totaling up to $780 million.
📋 Key Facts
- Entered into a License Agreement with Servier Pharmaceuticals LLC on March 18, 2025.
- Upfront payment of $70.0 million to Black Diamond Therapeutics.
- Potential milestone payments totaling up to $710.0 million based on development and commercial sales.
- Agreement includes tiered royalties based on global net sales.
- Servier will lead worldwide development and commercialization, including indications like non-small cell lung cancer.
Black Diamond Therapeutics, Inc. announced its financial results for the fiscal year and three months ended December 31, 2024. The filing serves as a formal announcement of year-end earnings/financial performance.
📋 Key Facts
- Report date: March 6, 2025
- Reporting period: Year and three months ended December 31, 2024
- The filing includes the release of financial results via Exhibit 99.1
- Company is an emerging growth company
Black Diamond Therapeutics, Inc. announced its financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Filing date: November 5, 2024.
- The filing is a standard announcement of quarterly/periodical financial results via Item 2.02.
Black Diamond Therapeutics has announced a major corporate restructuring plan involving the termination of its Chief Business Officer, CFO, and Principal Financial Officer, Fang Ni. The company is pivoting to focus resources on its lead program (BDTX-1535) and aims to extend its cash runway into Q2 2026 through cost-cutting measures.
🚩 Red Flags
- Simultaneous departure of key C-suite executives (CBO and CFO).
- Corporate restructuring involving a 'reduction in force' often indicates liquidity or burn rate concerns.
- Deprioritization of a development candidate (BDTX-4933) suggests a narrowing focus due to resource constraints.
📋 Key Facts
- Termination of Dr. Fang Ni as Chief Business Officer, CFO, and Principal Financial Officer effective October 7, 2024.
- Dr. Ni will provide unpaid advisory services through January 7, 2025.
- Erika Jones (SVP, Finance and Corporate Controller) appointed as interim Principal Financial Officer.
- Restructuring plan includes deprioritizing BDTX-4933 to seek collaboration partners.
- Restructuring involves a reduction in force and outsourcing of CMC activities.
- Company expects cost savings to extend cash runway into the second quarter of 2026.
Black Diamond Therapeutics announced positive preliminary Phase 2 data for its lead candidate, BDTX-1535, in patients with recurrent EGFRm non-small cell lung cancer (NSCLC). The data demonstrated a 42% objective response rate in the targeted patient subgroup and supported the selection of a 200 mg daily dose for pivotal development.
🚩 Red Flags
- None identified in this clinical data update.
📋 Key Facts
- Preliminary Objective Response Rate (ORR) of 42% achieved in 19 patients with known osimertinib resistance mutations.
- The 200 mg daily dose was selected for pivotal clinical development based on PK, safety, and tolerability data.
- Safety profile at 200 mg was considered favorable; most adverse events were mild or moderate (common: rash 70%, diarrhea 35%).
- Observed durability of response showed approximately 8 months or more for the first three patients with PR.
- Data cutoff date was August 17, 2024.
Black Diamond Therapeutics, Inc. announced its financial results for the three and six months ended June 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Announcement date: August 6, 2024.
- The filing includes Exhibit 99.1 containing the full text of the press release.
Black Diamond Therapeutics held its 2024 Annual Meeting of Stockholders on June 6, 2024. Shareholders approved the election of two Class I directors, ratified PricewaterhouseCoopers LLP as independent auditors, and approved an amendment to limit officer liability.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held virtually via live webcast on June 6, 2024.
- Prakash Raman and Mark A. Velleca were elected to the Board as Class I directors.
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year ending Dec 31, 2024.
- Stockholders approved a Certificate of Amendment to limit the liability of certain officers under Delaware law.
- Quorum was established with 46,716,888 shares present/represented out of 52,530,334 outstanding.
Black Diamond Therapeutics, Inc. announced its financial results for the three months ended March 31, 2024. The filing serves as a formal notice of the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Announcement date: May 9, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Black Diamond Therapeutics announced a restructuring of its Board of Directors on April 10, 2024. This involved the resignation of two directors and the appointment of two new independent directors.
🚩 Red Flags
- Departure of a committee chair (Wendy L. Dixon, Ph.D.) can sometimes signal internal shifts, though no disagreement was cited.
📋 Key Facts
- Alexander Mayweg, Ph.D. resigned from the Board effective April 10, 2024.
- Wendy L. Dixon, Ph.D. resigned from the Board and all committees (including Chair of Nominating and Corporate Governance) effective April 10, 2024.
- Both resigning directors stated their departures were not due to disagreements with the company's operations, policies, or practices.
- Prakash Raman, Ph.D. appointed as Class I director; will serve on Nominating and Corporate Governance and Audit Committees.
- Shannon Campbell appointed as Class III director; will serve on the Compensation Committee.
- Both new directors are deemed independent under Nasdaq listing standards.
Black Diamond Therapeutics, Inc. announced its financial results for the fiscal year and quarter ended December 31, 2023. The filing serves as a formal announcement of quarterly/annual earnings via an attached press release.
📋 Key Facts
- Reporting period: Year and three months ended December 31, 2023.
- Announcement date: March 12, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Black Diamond Therapeutics, Inc. announced the resignation of Rajeev Shah from the Board of Directors and the Audit Committee, effective January 17, 2024.
🚩 Red Flags
- Departure of an Audit Committee member can sometimes signal internal governance shifts, though no disagreement was cited here.
📋 Key Facts
- Rajeev Shah resigned from the Board of Directors and the Audit Committee on January 17, 2024.
- The resignation was effective immediately.
- Mr. Shah had served as a board member since December 2018.
- The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Black Diamond Therapeutics issued a corporate update and released an updated corporate presentation to communicate 2024 milestones to investors. The filing is primarily for regulatory compliance regarding the dissemination of non-public information under Regulation FD.
📋 Key Facts
- Company issued a press release titled 'Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones' on January 4, 2024.
- Updated corporate presentation was released for use in meetings with investors and analysts.
- The information provided under Item 7.01 is furnished but not filed for purposes of Section 18 liability.